PATH vs SERA
Uipath Inc (PATH) versus Sera Prognostics Inc (SERA) — a side-by-side from cached financials, not a winner call.
Uipath Inc (PATH) is a software - infrastructure company listed on US.
Sera Prognostics Inc (SERA) is a medical devices company listed on US.
Latest reported PATH revenue for 2026-01-31 was $1.61B. Net income was $282.3M. Revenue was up 12.7% from 2025-01-31 to 2026-01-31. PATH currently screens at market cap $6.07B and trailing P/E 19.4.
Latest reported SERA revenue for 2024-12-31 was $77.0K. Net income was -$32.9M. Revenue was down 74.8% from 2023-12-31 to 2024-12-31. SERA currently screens at market cap $89.1M.
PATH currently screens at market cap $6.07B and trailing P/E 19.4. SERA currently screens at market cap $89.1M.
Not investment advice. Open the PATH and SERA stock pages for the full models.
Not investment advice.